Aging drug discovery conference demonstrates tha

Highly anticipated conference returns to Switzer

Companies file joint patents relating to synergi

Collaboration between LT, Founders Forum and NUS

Targeting inflammatory diseases, company gears u

As ARDD gets underway, Life Bio’s CEO explains

DdrC protein repairs broken DNA fragments, resto

Mary Lou Jepsen’s latest $100m venture leverag

More than 160 speakers to present as the world’s largest aging drug discovery conference opens its doors. In the glorious settings of The University of Copenhagen, the largest conference on aging in the biopharmaceutical industry kicks off its proceedings today, beginning a full week of sessions, speakers and workshops. The 11th annual Aging Research and Drug Discovery conference (ARDD) once again brings together the world’s leading authorities on the science of aging and how to target the aging process in humans to enable healthier and longer lives for all. In addition to ARDD’s always stellar academic lineup, the 2024 conference boasts an incredibly strong presence from leading biotech companies in the aging field, further boosted by the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and others. Another significant focus of this year’s event is on longevity medicine, with an entire track dedicated to the translation from basic science towards the clinic and the implications for practicing physicians. ARDD’s home is in Denmark at the University of Copenhagen. Alongside Insilico Medicine boss Alex Zhavoronkov, ARDD is chaired by University of Copenhagen professors Morten Scheibye-Knudsen and Daniela Bakula. “I’m extremely happy about the program – we have an incredible lineup…

Victoria Forest on how a new longevity city in G

ALZpath CEO on building a scalable Alzheimer’s

Veteran pharmaceutical executive Jean-Pierre Gar

Company intends to expand its network of longevi

Finnish company claims its test is the first to

Investment will fund VNA-318, Vandria’s lead t

Company taps into Pfizer’s Boulder team as it

New data-powered digital health platform Thrive

New research reveals that certain antidiabetic d

Precision-fermented version of lactoferrin is li

Amid increasing concern over the validity of lon

MIT spinout leverages single strand DNA to ‘br

New clinical trial suggests donor stem cell trea

Company targets US metabolic health crisis, rais

Stanford Medicine study reveals we experience tw

Treating Alzheimer’s patients with combination

When you use links on our website, we may earn a f

The 11th ARDD conference will feature a star-stu

Topical treatment is designed to reactivate dorm

José Cordeiro and Felix Werth explore how the d

Genetic testing firm closes drug discovery divis

Researchers develop new method to create complex

Partnership aims to bring C2N’s portfolio of A

Preclinical study investigates neuron-targeted p

Unified company aims to ‘industrialize drug di

Bioniq founder on why taking a personalized appr

Companies seek to leverage disease risk detectio

Longevity world mourns a pioneer of aging resear

Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity of microglia, immune cells in the CNS that contribute to neuroinflammation. By modulating these cells, the company aims to reduce inflammation without disrupting the clearance of toxic proteins, thereby improving neuronal function and survival. Microglia, the central immune cells in the brain, can exist in two states: the neuroprotective M2 phenotype, which helps clear amyloid β, and the neurotoxic M1 phenotype, which contributes to inflammation and synaptic damage. In Alzheimer’s disease and other neurodegenerative conditions, there is an increased prevalence of the M1 state, exacerbating the disease. NeuroTherapia’s lead candidate, NTRX-07, is designed to activate the cannabinoid type 2 (CB2)…

New study shows that raising levels of fatty aci

On a mission to promote healthier eating habits,

Transferring regeneration-associated genes from

Company announces PIPE financing of up to $122 m

Part of $27 million fund to foster collaboration

New Alzheimer’s drug data highlights increased

Study identifies the nuclear protein Pin1 as piv

Seed round led by SV Health and Two Bear Capital

Study shows Shingrix vaccine may delay dementia

Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being the safety and tolerability of the treatment. The drug showed a consistent trend towards cognitive improvement across multiple measures, including an Alzheimer’s Disease Assessment Scale that involved 11 different tasks (ADAS-Cog 11) and a Mini-Mental State Examination based on 11 questions (MMSE). Specifically, by Day 182, participants on placebo experienced a 2.70-point decline on the ADAS-Cog 11 scale, while those on CT1812 showed a lesser decline of 1.66 points – indicating a 39% reduction in cognitive decline in favor of the treatment. Dr Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, remarked: “A key objective of this trial was to provide…

Recent study indicates that hyperbaric oxygen th

New research highlights inconsistency in lifespa